Market Access Aduhelm and an expensive failure to launch Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough.
Sales & Marketing Is the UK an attractive launch market? Leela Barham tries to cut through the lobbying to identify objective measures of the attractiveness of the UK market for launching new medicines.
Views & Analysis What makes a good (and bad) pharmaceutical forecast model Forecasting is essential in providing clarity on decision making about the future, but poor-quality forecasts can result in decisions which are commercially damaging to organisations.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
